🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Fruquintinib in Patients With Metastatic Colorectal Cancer

Recruitingn/aAges 18 Years - anyAlliOMEDICO AG
NCT06787105 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

FRUQUENT is an observational study in Germany. The goal of the study is to evaluate how well Fruquintinib works to treat patients with metastatic colorectal cancer that have previously been treated with available standard therapies. To this end, it will be analyzed how well patients respond to the therapy in the clinical routine. Further points of interest to the study are survival data, safety data, the use of medical care facilities, and the quality of life of patients treated with Fruquintinib. Participants will be treated as decided by the treating physician and according to their routine practice. FRUQUENT is accompanied by a translational research project combining real-world clinical data with foundational research to stratify patient collectives in regards to the therapeutic benefit of fruquintinib.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Aged 18 years or older. * Indication and decision for therapy with fruquintinib in accordance with the current German SmPC of fruquintinib as monotherapy for patients with mCRC. * Prior treatment with available standard therapies, including fluoropyrimidine-, oxaliplatin-, and irinotecan based chemotherapies, anti VEGF therapy, and if RAS wild-type, anti EGFR therapy. * Progression on or intolerance to treatment with either trifluridine/tipiracil and/or regorafenib. * Other criteria according to current SmPC. * Signed written informed consent.\* \* Patients are allowed to be enrolled up to 6 weeks after their first dose of fruquintinib. These patients cannot participate in the PRO assessments. Exclusion Criteria: * Participation in an interventional clinical trial (except follow-up) within 30 days prior to enrollment or start of treatment with fruquintinib, whatever comes first. * Contraindications according to current SmPC.
💊

What it tests

  • Not listed
📍

Where

42 sites
Hämatologikum Biberach
Biberach, Germany
Praxis für interdisziplinäre Onkologie & Hämatologie
Freiburg im Breisgau, Germany
Onkologische Schwerpunktpraxis
Heidelberg, Germany
MVZ für Hämatologie und Onkologie Ravensburg GmbH - Studienzentrum
Ravensburg, Germany
Zentrum Ambulante Onkologie
Schorndorf, Germany
ze:ro Praxen MVZ für Innere Medizin Weinheim
Weinheim, Germany
MVZ am Klinikum Aschaffenburg GmbH
Aschaffenburg, Germany
Schwerpunktpraxis Hämatologie & Internistische Onkologie
Fürth, Germany

…and 34 more on ClinicalTrials.gov.

🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy